Medigene announces market launch of Veregen® in Taiwan







Martinsried/Munich, 1 October 2013. Medigene AG (MDG, Frankfurt, Prime Standard) announced today that its partner SynCore, a member of the Sinphar Pharmaceutical Group, has started the launch of Veregen®, for the treatment of genital warts, in Taiwan.

Dr. Frank Mathias, Chief Executive Officer of Medigene AG, comments: "We are glad to announce that Veregen® is launched in the first country in Asia today. In cooperation with our partner SynCore, we will step by step open up the Asian countries included in our license agreement, and provide the patients in the growth market Asia with our drug."

Veregen® is already being marketed in the USA (by Fougera), in Germany, Austria and Switzerland (by Abbott), in Spain (by Bial), in Serbia (by Pharmanova) as well as in the Netherlands (by Will-Pharma) and approved in further countries. Medigene expects the launch of Veregen® in other countries within the next few months. Medigene has entered into numerous marketing partnerships for Veregen® across Europe, Asia, and America, and is planning to continue this global licensing strategy to further exploit the product's market potential.

About Veregen®: Veregen®, a topical treatment for external genital or perianal warts, contains a concentrate of catechins with a complex defined composition extracted from green tea leaves. In its current treatment guidelines for sexually transmitted diseases, the US Center for Disease Control and Prevention recommends Sinecatechins 15% ointment (Veregen®) as a possible option for treating genital warts. In addition, Sinecatechins 10% & 15% ointment (Veregen®) has been included in the current European guideline on the treatment of genital warts, the 2012 European Guideline for the Management of Anogenital Warts.

About SynCore: SynCore Biotechnology Co., Ltd, a joint venture between Sinphar Pharmaceutical Co., Ltd and the National Health Research Institute of Taiwan, is focused on the development of new drugs. Currently, SynCore has five products under development in different stages of clinical trial. Additionally, SynCore has been granted the exclusive development and marketing right in Asia for a new drug for the treatment of dry AMD (age-related macular degeneration) from MacuCLEAR, an US-based biotech company; the drug received approval to enter into phase II/III clinical trial in the US and Taiwan. For further information, please visit

About Sinphar Pharmaceutical: Sinphar Pharmaceutical Co, Ltd (Taiwan Stock Exchange, symbol: 1734), with subsidiaries in China and Canada, specializes in the sales and marketing of pharmaceutical products and dietary supplements as well as contract manufacture for several global pharma companies such as Johnson & Johnson, Takeda, Shionogi, and Astellas. Additionally, Sinphar is one of the major producers of paclitaxel (Phyxol®) in Asia. It is also involved in the research and development of botanical new drugs. Further information can be obtained at:

Medigene AG (Frankfurt: MDG, Prime Standard) is a publicly listed biotech company headquartered in Martinsried/Munich, Germany. Medigene focuses on clinical research and development of novel drugs against cancer and autoimmune diseases. Medigene is the first German biotech company to generate revenues from a marketed product (Veregen®), which is distributed by partner companies. Medigene also has two drug candidates undergoing clinical trials, EndoTAG®-1 und RhuDex®, and is developing an innovative vaccine technology. For further details, please visit

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® and Veregen® are registered trademarks of Medigene AG. Polyphenon E® is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or licensed in select locations only.

Julia Hofmann, Claudia Burmester
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01

To unsubscribe from the press release distribution list, please go to